Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06252519
Other study ID # PRO-FY2023-417
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 18, 2023
Est. completion date February 28, 2024

Study information

Verified date February 2024
Source University of Memphis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study compares three different formulations containing N-Acetyl Cysteine, with regards to acute absorption over a 24-hour period, following single ingestion. The formulations are traditional N-Acetyl Cysteine, N-Acetyl Cysteine Ethyl Ester, and a product containing a combination of N-Acetyl Cysteine Ethyl Ester, glycine, and two minerals with antioxidant potential (selenium and molybdenum) that might enhance the effect of N-Acetyl Cysteine Ethyl Ester. Subjects will report to the lab on three different occasions to consume the products, using a randomized cross-over design, and blood will be collected periodically (for the initial 8 hours and then again at 24 hours) per standard, routinely used pharmacokinetic /pharmacodynamic study protocols for evaluation of circulating glutathione concentrations. The hypothesis for this study is that the combination of N-Acetyl Cysteine Ethyl Ester + glycine will yield the greatest increase in glutathione, followed by N-Acetyl Cysteine Ethyl Ester, followed by N-Acetyl Cysteine. These findings will provide initial evidence specific to the bioavailability of these treatments following a single acute ingestion and may guide future recommendations regarding routine use.


Description:

One method of enhancing the uptake of N-Acetyl Cysteine following oral ingestion is to use the ethyl ester form, referred to as N-Acetyl Cysteine Ethyl Ester, which exerts remarkable antioxidant potential . N-Acetyl Cysteine Ethyl Ester is also available as a dietary supplement, has been well-investigated and known to be much more effective than traditional N-Acetyl Cysteine, in terms of elevating glutathione levels. In addition, recent work indicates that inclusion of the amino acid glycine along with very high dose N-Acetyl Cysteine results in an increase in glutathione, which may have health enhancing benefits for a variety of conditions. Such an elevation in glutathione may provide for antioxidant benefits which can reduce oxidative stress and possibly aid various aspects of overall health, as oxidative stress is associated with disease and aging. The study compares three different formulations containing N-Acetyl Cysteine, with regards to acute absorption over a 24-hour period, following single ingestion. The formulations are traditional N-Acetyl Cysteine, N-Acetyl Cysteine Ethyl Ester, and a product containing a combination of N-Acetyl Cysteine Ethyl Ester, glycine, and two minerals with antioxidant potential (selenium and molybdenum) that might enhance the effect of N-Acetyl Cysteine Ethyl Ester. Subjects will report to the lab on three different occasions to consume the products, using a randomized cross-over design, and blood will be collected periodically (for the initial 8 hours and then again at 24 hours) per standard, routinely used pharmacokinetic /pharmacodynamic study protocols for evaluation of circulating glutathione concentrations. The hypothesis for this study is that the combination of N-Acetyl Cysteine Ethyl Ester + glycine will yield the greatest increase in glutathione, followed by N-Acetyl Cysteine Ethyl Ester, followed by N-Acetyl Cysteine. These findings will provide initial evidence specific to the bioavailability of these treatments following a single acute ingestion and may guide future recommendations regarding routine use.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 8
Est. completion date February 28, 2024
Est. primary completion date December 13, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Recreationally active (2 or more days per week of exercise for greater than 30 minutes/day) - Body mass index between 18-29.9 kilograms per meter squared - fast overnight (greater than 10 hours) - willing to adhere to study procedures Exclusion Criteria: - tobacco user - chronic disease, including diagnosed digestive disorders - allergy or sensitivity to study product - alcohol consumption within 24 hours of study visit - caffeine consumption within 24 hours of study visit - active infection or illness - lactating, pregnant, planning to become pregnant during study

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
NAC
1 375 mg capsule containing N-acetyl cysteine
Neuro-NAC
3 capsules containing a total of 375 mg N-Acetyl L-Cysteine Ethyl Ester
Neuro-NAC XS
3 capsules containing a total of 75 mcg Selenium, 150 mcg Molybdenum, 1800 mg Glycine, and 375 mg N-Acetyl L-Cysteine Ethyl Ester

Locations

Country Name City State
United States Center for Nutraceutical and Dietary Supplement Research Memphis Tennessee

Sponsors (2)

Lead Sponsor Collaborator
University of Memphis Nature Fusions

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Heart Rate Heart Rate will be assessed in beats per minute using an automated blood pressure cuff. 0 min prior to supplement ingestion (baseline)
Other Heart Rate Heart Rate will be assessed in beats per minute using an automated blood pressure cuff. 0.25 hours following supplement ingestion
Other Heart Rate Heart Rate will be assessed in beats per minute using an automated blood pressure cuff. 0.5 hours following supplement ingestion
Other Heart Rate Heart Rate will be assessed in beats per minute using an automated blood pressure cuff. 1 hour following supplement ingestion
Other Heart Rate Heart Rate will be assessed in beats per minute using an automated blood pressure cuff. 1.5 hours following supplement ingestion
Other Heart Rate Heart Rate will be assessed in beats per minute using an automated blood pressure cuff. 2 hours following supplement ingestion
Other Heart Rate Heart Rate will be assessed in beats per minute using an automated blood pressure cuff. 4 hours following supplement ingestion
Other Heart Rate Heart Rate will be assessed in beats per minute using an automated blood pressure cuff. 6 hours following supplement ingestion
Other Heart Rate Heart Rate will be assessed in beats per minute using an automated blood pressure cuff. 8 hours following supplement ingestion
Other Heart Rate Heart Rate will be assessed in beats per minute using an automated blood pressure cuff. 24 hours following supplement ingestion
Other Diastolic Blood Pressure Diastolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 0 min prior to supplement ingestion (baseline)
Other Diastolic Blood Pressure Diastolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 0.25 hours following supplement ingestion
Other Diastolic Blood Pressure Diastolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 0.5 hours following supplement ingestion
Other Diastolic Blood Pressure Diastolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 1 hour following supplement ingestion
Other Diastolic Blood Pressure Diastolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 1.5 hours following supplement ingestion
Other Diastolic Blood Pressure Diastolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 2 hours following supplement ingestion
Other Diastolic Blood Pressure Diastolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 4 hours following supplement ingestion
Other Diastolic Blood Pressure Diastolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 6 hours following supplement ingestion
Other Diastolic Blood Pressure Diastolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 8 hours following supplement ingestion
Other Diastolic Blood Pressure Diastolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 24 hours following supplement ingestion
Other Systolic Blood Pressure Systolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 0 min prior to supplement ingestion (baseline)
Other Systolic Blood Pressure Systolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 0.25 hours following supplement ingestion
Other Systolic Blood Pressure Systolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 0.5 hours following supplement ingestion
Other Systolic Blood Pressure Systolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 1 hour following supplement ingestion
Other Systolic Blood Pressure Systolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 1.5 hours following supplement ingestion
Other Systolic Blood Pressure Systolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 2 hours following supplement ingestion
Other Systolic Blood Pressure Systolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 4 hours following supplement ingestion
Other Systolic Blood Pressure Systolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 6 hours following supplement ingestion
Other Systolic Blood Pressure Systolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 8 hours following supplement ingestion
Other Systolic Blood Pressure Systolic blood pressure will be assessed in millimeters mercury using an automated blood pressure cuff. 24 hours following supplement ingestion
Primary Area under the concentration curve for glutathione The area under the concentration curve for reduced glutathione over oxidized glutathione will be calculated for each supplement. 24 hour period following supplement ingestion
Primary Terminal Half-life of glutathione The terminal half-life of reduced glutathione over oxidized glutathione will be calculated for each supplement 24 hour period following supplement ingestion
Primary Peak concentration of glutathione The peak concentration of reduced glutathione over oxidized glutathione will be determined for each supplement 24 hour period following supplement ingestion
Primary Time to maximum concentration The time to reaching the maximum concentration of reduced glutathione over oxidized glutathione will be determined for each supplement 24 hour period following supplement ingestion
Primary Lag time The lag time of each supplement will be determined. 24 hour period following supplement ingestion
Primary Apparent volume distribution during terminal elimination phase The apparent volume distribution during terminal elimination phase will be determined for reduced glutathione over oxidized glutathione 24 hour period following supplement ingestion
Primary Oral Clearance of glutathione The oral clearance of each supplement will be determined. 24 hour period following supplement ingestion
Secondary Blood Malondialdehyde The concentration of malondialdehyde in blood will be measured in millimoles per liter 0 min prior to supplement ingestion (baseline)
Secondary Blood Malondialdehyde The concentration of malondialdehyde in blood will be measured millimoles per liter 2 hours following supplement ingestion
Secondary Blood Malondialdehyde The concentration of malondialdehyde in blood will be measured millimoles per liter 4 hours following supplement ingestion
Secondary Blood Malondialdehyde The concentration of malondialdehyde in blood will be measured millimoles per liter 8 hours following supplement ingestion
Secondary Blood Malondialdehyde The concentration of malondialdehyde in blood will be measured millimoles per liter 24 hours following supplement ingestion
Secondary Blood Advanced Oxidation Protein Products The concentration of blood advanced oxidation protein products will be measured in units of micromoles Chloramine per liter 0 min prior to supplement ingestion (baseline)
Secondary Blood Advanced Oxidation Protein Products The concentration of blood advanced oxidation protein products will be measured in units of micromoles Chloramine per liter 2 hours following supplement ingestion
Secondary Blood Advanced Oxidation Protein Products The concentration of blood advanced oxidation protein products will be measured in units of micromoles Chloramine per liter 4 hours following supplement ingestion
Secondary Blood Advanced Oxidation Protein Products The concentration of blood advanced oxidation protein products will be measured in units of micromoles Chloramine per liter 8 hours following supplement ingestion
Secondary Blood Advanced Oxidation Protein Products The concentration of blood advanced oxidation protein products will be measured in units of micromoles Chloramine per liter 24 hours following supplement ingestion
Secondary Brunel Mood Scale The brunel mood scale is a 24-item scale that consists of basic mood descriptors rated by the subject using a 5-point Likert scale where a score of 0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, and 4 = extremely. 0 min prior to supplement ingestion (baseline)
Secondary Brunel Mood Scale The brunel mood scale is a 24-item scale that consists of basic mood descriptors rated by the subject using a 5-point Likert scale where a score of 0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, and 4 = extremely. 2 hours following supplement ingestion
Secondary Brunel Mood Scale The brunel mood scale is a 24-item scale that consists of basic mood descriptors rated by the subject using a 5-point Likert scale where a score of 0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, and 4 = extremely. 4 hours following supplement ingestion
Secondary Brunel Mood Scale The brunel mood scale is a 24-item scale that consists of basic mood descriptors rated by the subject using a 5-point Likert scale where a score of 0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, and 4 = extremely. 8 hours following supplement ingestion
Secondary Brunel Mood Scale The brunel mood scale is a 24-item scale that consists of basic mood descriptors rated by the subject using a 5-point Likert scale where a score of 0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, and 4 = extremely. 24 hours following supplement ingestion
Secondary Subjective Feelings Subjective feelings will be self-assessed by subjects for energy, mood, motivation, focus, attention, irritability, and jitters the subject using a 100 mm visual analog scale from 0 (none) to 10 (extreme) 0 min prior to supplement ingestion (baseline)
Secondary Subjective Feelings Subjective feelings will be self-assessed by subjects for energy, mood, motivation, focus, attention, irritability, and jitters the subject using a 100 mm visual analog scale from 0 (none) to 10 (extreme) 2 hours following supplement ingestion
Secondary Subjective Feelings Subjective feelings will be self-assessed by subjects for energy, mood, motivation, focus, attention, irritability, and jitters the subject using a 100 mm visual analog scale from 0 (none) to 10 (extreme) 4 hours following supplement ingestion
Secondary Subjective Feelings Subjective feelings will be self-assessed by subjects for energy, mood, motivation, focus, attention, irritability, and jitters the subject using a 100 mm visual analog scale from 0 (none) to 10 (extreme) 8 hours following supplement ingestion
Secondary Subjective Feelings Subjective feelings will be self-assessed by subjects for energy, mood, motivation, focus, attention, irritability, and jitters the subject using a 100 mm visual analog scale from 0 (none) to 10 (extreme) 24 hours following supplement ingestion
See also
  Status Clinical Trial Phase
Completed NCT04092725 - Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects Phase 1
Completed NCT04181008 - Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers Early Phase 1
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed NCT04406415 - Oral Nafamostat in Healthy Volunteers Phase 1
Not yet recruiting NCT05421312 - Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip Phase 4
Completed NCT02534753 - A Pharmacokinetics Study of Intravenous Ascorbic Acid Phase 1
Completed NCT01682408 - Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability Phase 1
Completed NCT01976078 - Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents N/A
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01208155 - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets Phase 1
Completed NCT01214941 - Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol Phase 4
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01260025 - Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor Phase 1
Completed NCT00856570 - A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects Phase 1
Completed NCT00984009 - A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice Phase 1
Completed NCT00730145 - A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis Phase 1
Completed NCT01276119 - The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males Phase 1
Completed NCT01055964 - a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients Phase 3
Completed NCT00746499 - Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women. Phase 1
Completed NCT00747721 - Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU Phase 1